Pars Pharmaceutical Consulting Revenue and Competitors
Estimated Revenue & Valuation
- Pars Pharmaceutical Consulting's estimated annual revenue is currently $5.6M per year.
- Pars Pharmaceutical Consulting's estimated revenue per employee is $201,000
Employee Data
- Pars Pharmaceutical Consulting has 28 Employees.
- Pars Pharmaceutical Consulting grew their employee count by -3% last year.
Pars Pharmaceutical Consulting's People
Name | Title | Email/Phone |
---|
Pars Pharmaceutical Consulting Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $22.9M | 114 | 24% | N/A | N/A |
#2 | $1105.9M | 5502 | 3% | N/A | N/A |
#3 | $47M | 234 | 26% | N/A | N/A |
#4 | $9.2M | 46 | 5% | N/A | N/A |
#5 | $10192.5M | 50709 | 3% | N/A | N/A |
#6 | $6M | 30 | 0% | N/A | N/A |
#7 | $110.1M | 548 | 9% | N/A | N/A |
#8 | $8.8M | 44 | -2% | N/A | N/A |
#9 | $21.3M | 106 | -27% | N/A | N/A |
#10 | $27.7M | 138 | -28% | N/A | N/A |
What Is Pars Pharmaceutical Consulting?
Our mission at Pars Pharmaceuticals Consulting (PPC) is to provide efficient and cost effective product development and regulatory support to biotech and pharmaceutical companies. The Senior Management Team and Advisors at PPC are pharmaceutical industry executives with comprehensive knowledge of drug discovery and development. Our team members have led the discovery and development of many drugs through different stages of preclinical and clinical development in small to mid-size private and public entrepreneurial environments. We fully understand the ongoing challenges of meeting corporate drug development milestones and have the experience and insight to assist in achieving these goals in a timely and cost efficient manner.
keywords:N/AN/A
Total Funding
28
Number of Employees
$5.6M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 30 | 3% | N/A |
#2 | $4.5M | 32 | 3% | N/A |
#3 | $8.5M | 33 | 3% | N/A |
#4 | $9.1M | 35 | 6% | N/A |
#5 | $4.5M | 35 | 6% | N/A |